SLC13A5 and metabolic dysfunction-associated steatotic liver disease: More importantly, Loeffelholz et al. reported that SLC13A5 gene expression levels were significantly increased and independently correlated with hepatic steatosis in liver samples from NAFLD patients with obesity for the first time (von Loeffelholz et al., 2017), revealing the relationship between NACT and hepatic steatosis in humans.